We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

Novel Patch-Based Ebolavirus Diagnostic to Help Quickly Identify and Treat Infected Individuals

By LabMedica International staff writers
Posted on 22 Aug 2023
Print article
Image: The SatioDot dried blood spot collection patch (Photo courtesy of Satio)
Image: The SatioDot dried blood spot collection patch (Photo courtesy of Satio)

A groundbreaking diagnostic that combines a patch-based blood collection device with a sensitive and rapid immunoassay for ebolavirus into a single device will allow community health workers to quickly identify and treat infected individuals in remote settings.

The novel, single-use, rapid ebolavirus diagnostic will combine Satio, Inc.’s (Boston, MA, USA) patch-based blood collection device with an ebolavirus immunoassay from Institut Pasteur de Dakar (Dakar, Senegal). Satio is working on a suite of patch-based platforms, including SatioDot optimized for dried blood spots, and SatioDraw designed for comprehensive whole blood collection, which can cater to an extensive array of lab-based tests. These platforms employ a lancet to gather blood from the upper arm, channeling it into the patch. Satio is now accelerating the development of an integrated blood draw and diagnostic platform with the potential to extend its capabilities for identifying other critical blood-borne pathogens, such as HIV and syphilis.

Satio's groundbreaking designs, covered by patent protection, provide patients with access to simple and cost-effective blood collection options. These solutions facilitate blood extraction, reagent mixing, and the identification of an array of pathogens, all achieved through a patch affixed to the arm. In a remarkable extension, Satio's patch technology also holds the potential for the painless administration of drugs and vaccines. Consequently, this innovation holds the promise to mitigate or even eliminate the necessity for needles and medical professional intervention. By doing away with conventional fingerstick blood samples and the associated external blood sample manipulation, Satio's trailblazing innovation reduces exposure to bloodborne pathogens. Simultaneously, it offers an exceptional, budget-friendly diagnostic tool for easy deployment at the point of need, thereby advancing patient outcomes and restricting the spread of ebolavirus.

Related Links:
Satio, Inc.
Institut Pasteur de Dakar 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
POCT Fluorescent Immunoassay Analyzer
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article


Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more


view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.